CD

Jonathan Porter Appointed as CD&R Funds Operating Advisor

Retrieved on: 
Tuesday, October 17, 2023
Knowledge, Babson College, CD, Clayton, Dubilier & Rice, Culture, R, Health, Ageing, Software, Data analysis, Business administration, Dubilier, CD&R, Patient, Pharmaceutical industry, Management, Nursing, Science

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Clayton, Dubilier & Rice ("CD&R" or the "Firm") today announced the appointment of Jonathan Porter as an Operating Advisor to CD&R funds. Mr. Porter will draw on his more than 25 years of experience leading business and commercial functions within the healthcare sector to support CD&R in identifying and evaluating new investment opportunities in healthcare information technology, software and tech-enabled services businesses.

Key Points: 
  • NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Clayton, Dubilier & Rice ("CD&R" or the "Firm") today announced the appointment of Jonathan Porter as an Operating Advisor to CD&R funds.
  • Mr. Porter is the former Chief Product Officer at Bright Health Group, a technology-enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, with responsibility for the design and delivery of its comprehensive technology strategy.
  • During his tenure with Bright Health Group, Mr. Porter also served as CEO of DocSquad, the company's provider-facing and virtual care platform launched in 2021.
  • Mr. Porter received a Bachelor of Science in Business Administration at Babson College.

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease

Retrieved on: 
Monday, October 16, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Incidence, European Commission, Health care, United European Gastroenterology, Northwestern Medicine, Feinberg School of Medicine, Mayo, CD, Aes, MD, BLA, IBD, Crohn's disease, Safety, Medicine, Ulcerative colitis, Patient, FDA, Biologics license application, Celltrion, CDAI, Maintenance, Infliximab, Inflammatory bowel disease, UEG, Infection, Pharmaceutical industry, Medical imaging, UC

The proportion of patients who experienced adverse events (AEs), serious AEs, infection in the SC infliximab and placebo groups were generally comparable.

Key Points: 
  • The proportion of patients who experienced adverse events (AEs), serious AEs, infection in the SC infliximab and placebo groups were generally comparable.
  • If approved by the FDA, CT-P13 SC would be the first subcutaneous formulation of infliximab.
  • Post-hoc analyses of the LIBERTY-CD and LIBERTY-UC studies were presented as posters at UEG Week 2023.
  • The first post-hoc analysis examined the possible use of SC infliximab treatment without immunosuppressants and the second evaluated dose escalation in patients with loss of treatment response.

Myrtelle Announces Presentation of Positive 12-month Post Treatment Data in its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy at the 2023 Cell & Gene Meeting on the Mesa held by the Alliance for Regenerative Medicine

Retrieved on: 
Tuesday, October 10, 2023
Research, Neurology, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Canavan disease, FIH, ASPA, White matter, Regenerative medicine, CD, Cell, Inc., Gene, Mutation, Tissue engineering, Clinical trial, Preyasi Raave, Gene editing, Natural history, Patient, Medical device

In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.

Key Points: 
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.
  • Following gene therapy, statistically significant gains in certain target white matter and myelin were observed.
  • In turn, improvements in multiple domains on the validated Gross Motor Function Measure and Mullen Scales of Early Learning were demonstrated.
  • Treated patients were routinely observed to outperform untreated age-matched natural history patients on the Mullen Scale of Early Learning.

AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023

Retrieved on: 
Tuesday, October 10, 2023
Congress, NYSE, United European Gastroenterology, UC, Ustekinumab, Abstract, INSPIRE, Inflammation, CD, MD, Maintenance, ABBV, IBD, Crohn's disease, Safety, University, AbbVie, Medicine, NORTH, CEST, Ulcerative colitis, Patient, Risankizumab, Inflammatory Bowel Diseases, Research, UEG, University of Calgary, Doctor of Pharmacy, Boehringer Ingelheim, Poster, Pharmaceutical industry

NORTH CHICAGO, Ill., Oct. 10, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral presentations and 12 poster presentations spanning research on risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn's disease (CD) and ulcerative colitis (UC).

Key Points: 
  • AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral presentations and 12 poster presentations spanning research on risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn's disease (CD) and ulcerative colitis (UC).
  • "Our continued commitment to research in IBD demonstrates our relentless quest to elevating standards of care for those living with disruptive gastroenterological conditions," said Sofie Berg, PharmD, Ph.D., head of gastroenterology, global medical affairs, AbbVie.
  • "The research that will be presented by AbbVie at UEG Week 2023 will advance knowledge to better address how new therapies may further benefit patients with these challenging conditions with the aim to maximize clinical and endoscopic outcomes."
  • SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

NACDD Announces Impact Award Winners and New Board of Directors

Retrieved on: 
Friday, September 29, 2023
BLS, CD, Washington State Department of Labor and Industries, Rising Star Award, Doctor of Public Health, Massachusetts Department of Public Health, Arkansas Department of Health, MSN, Maryland Department of Commerce, Ojamaa, Public, Bureau, Health promotion, Health equity, FNP, Performing arts of Australia, Utah Department of Health, TIME100 Impact Awards, New York State Department of Health, CHES, RDN, Doctor of Philosophy, NCD, DNP, MHS, FAAFP, -elect, Public health, Large, Non-communicable disease, Division, Maryland Department of Health, Family nurse practitioner, Chronic condition, Control, National Association, MPH, Washington State Department of Health, Community health, Pharmaceutical industry, Management, Nursing, MD

ATLANTA, Sept. 29, 2023 /PRNewswire/ -- The National Association of Chronic Disease Directors (NACDD) announced the winners of the 2023 Impact Awards as well as its new Board of Directors during the Annual Business Meeting held Sept. 26.

Key Points: 
  • ATLANTA, Sept. 29, 2023 /PRNewswire/ -- The National Association of Chronic Disease Directors (NACDD) announced the winners of the 2023 Impact Awards as well as its new Board of Directors during the Annual Business Meeting held Sept. 26.
  • The Impact Awards are nominated by NACDD Members and selected by a committee who evaluate the applications to identify the greatest impact on chronic disease prevention and control and health promotion.
  • "The passion, dedication, and innovation shown by NACDD Members across our states and territories is truly inspiring!
  • The newly elected At Large Directors are:
    Victoria Ballares, MSN, DNP, FNP, BLS, a board certified Family Nurse Practitioner in Guam.

Myrtelle Announces Presentation at Hydrocephalus Association & Rudi Schulte Research Workshop on Developing Non-Invasive Hydrocephalus Therapies: Molecular and Cellular Targets

Retrieved on: 
Thursday, September 28, 2023
Health, Neurology, Genetics, Clinical Trials, Research, Science, Biotechnology, CD, Canavan disease, Inc., Natural history, Gene, Clinical trial, Mutation, ASPA, Associate, Chromosome 11, MRI, Magnetic resonance imaging, Patient, Preyasi Raave, White matter, Hydrocephalus, FIH, Medical imaging

These improvements in treated patients contrast the deterioration in untreated age-matched CD patients based on natural history.

Key Points: 
  • These improvements in treated patients contrast the deterioration in untreated age-matched CD patients based on natural history.
  • MRI-based improvements are correlated with improvements in motor and cognitive function in treated patients, which will be presented at upcoming conferences.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.
  • The oligodendrocyte-targeting rAAV vector-based gene therapy is intended to restore ASPA function and brain development in patients with CD.

White Cap Announces CEO Retirement and Succession Plan

Retrieved on: 
Tuesday, September 26, 2023
CD, Learning, Operation, Partnership, Culture, Sustainability reporting, St. Jude Children's Research Hospital, HD Supply, CCO, The Home Depot, Sustainability, Acquisition, Atlanta, Knowledge, Growth, Hospital, Small Business Saturday, CD&R, The Atlanta Journal-Constitution, Cryptocurrency, Management, Michigan City White Caps

ATLANTA, Sept. 26, 2023 /PRNewswire/ -- White Cap, the leading distributor of specialty construction supplies and safety products for professional contractors, today announced that John Stegeman has made the decision to retire from his position as Chief Executive Officer (CEO) of White Cap effective January 28, 2024. Concurrently, as part of the multiyear succession plan, the White Cap board of directors has approved the promotion of Alan Sollenberger, President of White Cap, to CEO effective January 29, 2024.  

Key Points: 
  • Concurrently, as part of the multiyear succession plan, the White Cap board of directors has approved the promotion of Alan Sollenberger, President of White Cap, to CEO effective January 29, 2024.
  • John and Alan have partnered closely on all White Cap company strategy and business decisions following Alan's appointments to Chief Financial Officer of White Cap in 2010 and President in 2020.
  • "The last 14 years spent serving our associates and customers at White Cap has been the highlight of my professional career," said John Stegeman, CEO of White Cap.
  • As part of the transition, Page Naftel, Chief Sales Officer of White Cap, has been promoted to Chief Commercial Officer (CCO) of White Cap, reporting to Alan Sollenberger.

Dame Olivia Newton-John’s Totally Hot Celebrates 45th Anniversary With a Sizzling Return to Vinyl and CD on November 17

Retrieved on: 
Friday, September 22, 2023
Celebrity, Entertainment, Music, Newton, CD, RIAA, Neon, Totally Hot, Platinum, Multimedia, UK Singles Chart, The Spencer Davis Group, Top 10 Hits of the End of the World, Digital, Cassette tape

In celebration of Newton-John’s first-ever platinum-certified album’s 45th anniversary, Totally Hot returns to vinyl for the first time in decades in two different options, in addition to being made available anew on CD and on all major digital platforms.

Key Points: 
  • In celebration of Newton-John’s first-ever platinum-certified album’s 45th anniversary, Totally Hot returns to vinyl for the first time in decades in two different options, in addition to being made available anew on CD and on all major digital platforms.
  • View the full release here: https://www.businesswire.com/news/home/20230922555403/en/
    Dame Olivia Newton-John’s Totally Hot Celebrates 45th Anniversary With a Sizzling Return to Vinyl and CD on November 17 (Graphic: UMe)
    Totally Hot will be released in the following formats: limited-edition 1LP neon coral red vinyl, standard weight 1LP black vinyl, 1CD, and Digital.
  • Produced by Newton-John’s longtime collaborator John Farrar, Totally Hot featured 10 tracks and two big hit singles.
  • Totally Hot also reached the Top 10 in Canada, the Netherlands, Norway, and Sweden.

LA Kings Welcome Custodio & Dubey as the NHL Team’s Official Law Firm

Retrieved on: 
Thursday, September 21, 2023
Professional Services, Hockey, Entertainment, Sports, General Entertainment, Legal, Events, Concerts, Crypto.com, CD, Heart, Insurance, Partnership, Senior, Life, Marketing, Domestic violence, NHL, Kings, Multimedia, Crypto.com Arena, History, Element, Guiding Eyes for the Blind, Philosophy, LED, Ice, Dog, Hall, Sport, Growth, AEG, Video game, Chicken à la King, Custódio, Los Angeles Kings

Two-time Stanley Cup Champions, the LA Kings have launched a strategic new marketing partnership with leading personal injury law firm, Custodio & Dubey LLP (CD Law).

Key Points: 
  • Two-time Stanley Cup Champions, the LA Kings have launched a strategic new marketing partnership with leading personal injury law firm, Custodio & Dubey LLP (CD Law).
  • As part of the multi-year agreement, brokered by AEG Global Partnerships, CD Law will become the official law firm of the NHL team, strengthening its ties to millions of passionate sports fans across Southern California.
  • View the full release here: https://www.businesswire.com/news/home/20230921676892/en/
    CD LAW partners and co-founders Vineet Dubey and Miguel Custodio are joined by LA Kings mascot Bailey to celebrate CD LAW's new marketing partnership with the LA Kings.
  • (Photo: Business Wire)
    “We are delighted to extend a warm welcome to CD Law as the official law firm of our team.

Clearpath Revolutionizes Medical Image Sharing with AI-powered Patient Solution

Retrieved on: 
Tuesday, September 19, 2023
FARMS, CD, Natural language processing, CT, Partnership, CTS, Record, Android, Electronic health record, Radiology, NLP, IOS, Magnetic resonance imaging, Patient, EHR, Physician, Artificial intelligence, Health, PACS, Medical imaging, Clearpath Robotics

BINGHAM FARMS, Mich., Sept. 19, 2023 /PRNewswire/ -- Clearpath Technologies announced today the launch of its patient solution, PatientConnect, which it developed in partnership with leading healthcare facilities.

Key Points: 
  • Clearpath for Patients empowers healthcare facilities to deliver next-generation patient experiences by sharing x-rays, MRIs, and CT-scans digitally.
  • BINGHAM FARMS, Mich., Sept. 19, 2023 /PRNewswire/ -- Clearpath Technologies announced today the launch of its patient solution, PatientConnect, which it developed in partnership with leading healthcare facilities.
  • "Many health systems believe they have an image sharing solution in place, but these legacy systems are limited........"
    Before Clearpath, patients had to wait days or weeks after an appointment to receive their medical imaging via CD.
  • "Our goal is to be a driving force in the digital transformation of medical record and image sharing," said Lauren Brown, Clearpath's President.